{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:22:43Z","timestamp":1773523363580,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,29]]},"DOI":"10.7759\/cureus.98067","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:55:13Z","timestamp":1764417313000},"source":"Crossref","is-referenced-by-count":1,"title":["Acute Drug-Induced Hepatitis Associated With Vortioxetine: A Case Report"],"prefix":"10.7759","author":[{"given":"Carolina","family":"Guimar\u00e3es","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Hip\u00f3lito Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge S","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4065\/74.7.692","article-title":"Acute hepatitis due to fluoxetine therapy","volume":"74","author":"Cai Q","year":"1999","unstructured":"Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL, Kirchner JP. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc. 1999, 74:692-4. 10.4065\/74.7.692","journal-title":"Mayo Clin Proc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","author":"European Association for the Study of the Liver (EASL)","year":"2019","unstructured":"European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019, 70:1222-61. 10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-07987-1","article-title":"Use of vortioxetine in different neurological fields: a systematic review and future perspectives","volume":"46","author":"Verrienti G","year":"2025","unstructured":"Verrienti G, Colonna I, Raccagni C. Use of vortioxetine in different neurological fields: a systematic review and future perspectives. Neurol Sci. 2025, 46:2055-71. 10.1007\/s10072-025-07987-1","journal-title":"Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00597-3","article-title":"Effectiveness of vortioxetine in patients with major depressive disorder associated with chronic pain: an observational study in a Spanish population","volume":"13","author":"Folch Ib\u00e1\u00f1ez J","year":"2024","unstructured":"Folch Ib\u00e1\u00f1ez J, Vargas Domingo M, Coma Alemany J, Callao S\u00e1nchez R, Guitart Vela J. Effectiveness of vortioxetine in patients with major depressive disorder associated with chronic pain: an observational study in a Spanish population. Pain Ther. 2024, 13:621-35. 10.1007\/s40122-024-00597-3","journal-title":"Pain Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-13786-7","article-title":"A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system","volume":"15","author":"Liu M","year":"2025","unstructured":"Liu M, Xia Y, Long W, Han X, Xiong Y. A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system. Sci Rep. 2025, 15:28886. 10.1038\/s41598-025-13786-7","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13050709","article-title":"Antidepressant-induced liver injury: a review for clinicians","volume":"171","author":"Voican CS","year":"2014","unstructured":"Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014, 171:404-15. 10.1176\/appi.ajp.2013.13050709","journal-title":"Am J Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02963-4","article-title":"Antidepressants- and antipsychotics-induced hepatotoxicity","volume":"95","author":"Todorovi\u0107 Vukoti\u0107 N","year":"2021","unstructured":"Todorovi\u0107 Vukoti\u0107 N, \u0110or\u0111evi\u0107 J, Peji\u0107 S, \u0110or\u0111evi\u0107 N, Pajovi\u0107 SB. Antidepressants- and antipsychotics-induced hepatotoxicity. Arch Toxicol. 2021, 95:767-89. 10.1007\/s00204-020-02963-4","journal-title":"Arch Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi PH","year":"2022","unstructured":"Hayashi PH, Lucena MI, Fontana RJ, et al.. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022, 76:18-31. 10.1002\/hep.32327","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s1130-6343(08)72814-9","article-title":"Sertraline-induced hepatotoxicity (Article in Spanish)","volume":"32","author":"Collados Arroyo V","year":"2008","unstructured":"Collados Arroyo V, Plaza Aniorte J, Hallal H, P\u00e9rez-Cuadrado E. Sertraline-induced hepatotoxicity (Article in Spanish). Farm Hosp. 2008, 32:60-1. 10.1016\/s1130-6343(08)72814-9","journal-title":"Farm Hosp"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0524-3","article-title":"Sertraline hepatotoxicity: report of a case and review of the literature","volume":"54","author":"Tabak F","year":"2009","unstructured":"Tabak F, Gunduz F, Tahan V, Tabak O, Ozaras R. Sertraline hepatotoxicity: report of a case and review of the literature. Dig Dis Sci. 2009, 54:1589-91. 10.1007\/s10620-008-0524-3","journal-title":"Dig Dis Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1456455","article-title":"Sertraline induced acute hepatocellular liver injury in patient with major depressive disorder: a case report","volume":"15","author":"Renemane L","year":"2024","unstructured":"Renemane L, Rancans E. Sertraline induced acute hepatocellular liver injury in patient with major depressive disorder: a case report. Front Psychiatry. 2024, 15:1456455. 10.3389\/fpsyt.2024.1456455","journal-title":"Front Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0583-5","article-title":"Antidepressant-induced acute liver injury: a case-control study in an Italian inpatient population","volume":"41","author":"Ferrajolo C","year":"2018","unstructured":"Ferrajolo C, Scavone C, Donati M, et al.. Antidepressant-induced acute liver injury: a case-control study in an Italian inpatient population. Drug Saf. 2018, 41:95-102. 10.1007\/s40264-017-0583-5","journal-title":"Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-201022","article-title":"Acute liver injury secondary to sertraline","volume":"2013","author":"Suen CF","year":"2013","unstructured":"Suen CF, Boyapati R, Simpson I, Dev A. Acute liver injury secondary to sertraline. BMJ Case Rep. 2013, 2013:14-6. 10.1136\/bcr-2013-201022","journal-title":"BMJ Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K114","article-title":"Antidepressant-induced liver injury","volume":"41","author":"DeSanty KP","year":"2007","unstructured":"DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother. 2007, 41:1201-11. 10.1345\/aph.1K114","journal-title":"Ann Pharmacother"},{"key":"ref15","article-title":"Drug-induced hepatitis due to hypersensitivity (Article in Portuguese)","volume":"2","author":"Maria VA","year":"1994","unstructured":"Maria VA, Victorino RM. Drug-induced hepatitis due to hypersensitivity (Article in Portuguese). Rev Port Imunoalergol. 1994, 2:151-8.","journal-title":"Rev Port Imunoalergol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v63n0208","article-title":"Hepatotoxicity associated with the new antidepressants","volume":"63","author":"Carvajal Garc\u00eda-Pando A","year":"2002","unstructured":"Carvajal Garc\u00eda-Pando A, Garc\u00eda del Pozo J, S\u00e1nchez AS, Velasco MA, Rueda de Castro AM, Lucena MI. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry. 2002, 63:135-7. 10.4088\/jcp.v63n0208","journal-title":"J Clin Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/10408360701713112","article-title":"Relevant issues in the monitoring and the toxicology of antidepressants","volume":"45","author":"Wille SM","year":"2008","unstructured":"Wille SM, Cooreman SG, Neels HM, Lambert WE. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci. 2008, 45:25-89. 10.1080\/10408360701713112","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01139-y","article-title":"Post-marketing safety profile of vortioxetine using a cluster analysis and a disproportionality analysis of global adverse event reports","volume":"45","author":"Ekhart C","year":"2022","unstructured":"Ekhart C, van Hunsel F, van Puijenbroek E, Chandler R, Meldau EL, Taavola H, Nor\u00e9n GN. Post-marketing safety profile of vortioxetine using a cluster analysis and a disproportionality analysis of global adverse event reports. Drug Saf. 2022, 45:145-53. 10.1007\/s40264-021-01139-y","journal-title":"Drug Saf"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2443956","article-title":"The antidepressants and sexual dysfunction: a pharmacovigilance-pharmacodynamic study of the FDA adverse event reporting system","volume":"4","author":"Cheng Y","year":"2024","unstructured":"Cheng Y, Chen Y, Zhao X, et al.. The antidepressants and sexual dysfunction: a pharmacovigilance-pharmacodynamic study of the FDA adverse event reporting system. Expert Opin Drug Saf. 2024, 4:1-11. 10.1080\/14740338.2024.2443956","journal-title":"Expert Opin Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1519865","article-title":"Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system","volume":"16","author":"Li L","year":"2025","unstructured":"Li L, Xu Q, Pang L, Liu Y, Lu Y. Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system. Front Pharmacol. 2025, 16:1519865. 10.3389\/fphar.2025.1519865","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14r09164","article-title":"The US Food and Drug Administration's perspective on the new antidepressant vortioxetine","volume":"76","author":"Zhang J","year":"2015","unstructured":"Zhang J, Mathis MV, Sellers JW, et al.. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. J Clin Psychiatry. 2015, 76:8-14. 10.4088\/JCP.14r09164","journal-title":"J Clin Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2505692","article-title":"Vortioxetine in the routine management of major depressive disorder: an analysis of European automated healthcare databases","volume":"41","author":"Andersohn F","year":"2025","unstructured":"Andersohn F, Christensen MC, Creuwels L, et al.. Vortioxetine in the routine management of major depressive disorder: an analysis of European automated healthcare databases. Curr Med Res Opin. 2025, 41:867-77. 10.1080\/03007995.2025.2505692","journal-title":"Curr Med Res Opin"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin DS","year":"2016","unstructured":"Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016, 30:242-52. 10.1177\/0269881116628440","journal-title":"J Psychopharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2.3.249","article-title":"Antidepressant-induced hepatotoxicity","volume":"2","author":"Lucena MI","year":"2003","unstructured":"Lucena MI, Carvajal A, Andrade RJ, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf. 2003, 2:249-62. 10.1517\/14740338.2.3.249","journal-title":"Expert Opin Drug Saf"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-024-04447-9","article-title":"The ameliorating effect of Rutin on hepatotoxicity and inflammation induced by the daily administration of vortioxetine in rats","volume":"24","author":"Anwar MM","year":"2024","unstructured":"Anwar MM, Laila IM. The ameliorating effect of Rutin on hepatotoxicity and inflammation induced by the daily administration of vortioxetine in rats. BMC Complement Med Ther. 2024, 24:153. 10.1186\/s12906-024-04447-9","journal-title":"BMC Complement Med Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani N","year":"2008","unstructured":"Chalasani N, Fontana RJ, Bonkovsky HL, et al.. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008, 135:1924-34. 10.1053\/j.gastro.2008.09.011","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1023\/a:1023007831047","article-title":"Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity","volume":"48","author":"Persky S","year":"2003","unstructured":"Persky S, Reinus JF. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig Dis Sci. 2003, 48:939-44. 10.1023\/a:1023007831047","journal-title":"Dig Dis Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.876868","article-title":"N-acetylcysteine for the management of non-acetaminophen drug-induced liver injury in adults: a systematic review","volume":"13","author":"Sanabria-Cabrera J","year":"2022","unstructured":"Sanabria-Cabrera J, Tabbai S, Niu H, et al.. N-acetylcysteine for the management of non-acetaminophen drug-induced liver injury in adults: a systematic review. Front Pharmacol. 2022, 13:876868. 10.3389\/fphar.2022.876868","journal-title":"Front Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3348","article-title":"A case report of a drug-induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing","volume":"8","author":"Gonz\u00e1lez-Mu\u00f1oz M","year":"2020","unstructured":"Gonz\u00e1lez-Mu\u00f1oz M, Monserrat Villatoro J, Mar\u00edn-Serrano E, et al.. A case report of a drug-induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing. Clin Case Rep. 2020, 8:3105-9. 10.1002\/ccr3.3348","journal-title":"Clin Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433285-acute-drug-induced-hepatitis-associated-with-vortioxetine-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:55:14Z","timestamp":1764417314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433285-acute-drug-induced-hepatitis-associated-with-vortioxetine-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.98067","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,29]]}}}